Enanta reports Q4 EPS (87c), consensus ($1.01)

Reports Q4 revenue $15.1M, consensus $15.97M. “This past quarter marked a pivotal period for Enanta (ENTA), with significant progress across our virology and immunology programs, highlighted by positive topline data from the RSVHR study, our Phase 2b clinical trial in high-risk adults infected with RSV. These Phase 3-enabling results underscore zelicapavir’s ability to meaningfully reduce the duration of RSV symptoms and represent the first time an antiviral treatment demonstrated a clinically meaningful benefit in high-risk adult outpatients with RSV,” said Jay R. Luly, Ph.D., President and Chief Executive Officer at Enanta Pharmaceuticals. “In parallel, we reached an important milestone for our oral STAT6 program with the selection of EPS-3903 as our lead development candidate for the treatment of type 2 immune-driven diseases. This novel, potent and selective inhibitor has demonstrated rapid, continuous and complete pSTAT6 suppression of greater than 90%, and efficacy comparable to dupilumab in multiple asthma and atopic dermatitis disease mouse models after oral dosing. We look forward to filing an Investigational New Drug application for this program in the second half of 2026. Additionally, we have nominated EDP-978 as our oral, once-daily KIT inhibitor clinical candidate for the treatment of mast-cell driven diseases, with plans to file an IND in the first quarter of 2026. Taken together, this progress underscores our commitment to developing small molecule treatments for immunological diseases.”